Diabetologie und Stoffwechsel 2024; 19(S 01): S74
DOI: 10.1055/s-0044-1785382
Abstracts | DDG 2024
Poster
Posterwalk 10 – GLP-1 Agonisten, Doppel- und Mehrfachagonisten bei Typ-2-Diabetes

Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)

Authors

  • Kristina Boye

    1   Eli Lilly and Company, Value Evidence Outcomes – Diabetes, Indianapolis, IN, United States

  • Helene Sapin

    2   Eli Lilly and Company, Statistics – RWA2 – RWE – Market Access, Indianapolis, IN, United States

  • Jiat Ling Poon

    3   Eli Lilly and Company, VEO – Center of Innovation, Indianapolis, IN, United States

  • Laura Fernández Landó

    4   Eli Lilly and Company, Incretin Portfolio Development, Indianapolis, IN, United States

  • Ruth Huh

    5   Eli Lilly and Company, Statistics Innovation Center, Indianapolis, IN, United States

  • Mianbo Wang

    6   Syneos Health, Biostatistician, Morrisville, NC, United States

  • Hiren Patel

    7   Eli Lilly and Company, Type 2 Diabetes Development, Indianapolis, IN, United States

  • Bernd-M. Scholz

    8   Diabetologische Schwerpunktpraxis Harburg, Germany, Internal Medicine and Diabetologists, Hamburg, Germany
Weitere Informationen
Auch verfügbar auf
 

Does tirzepatide (TZP) improve HRQoL compared to insulin lispro (iLispro) in adults with type 2 diabetes (T2D) treated with basal insulin?

Methods: In SURPASS-6, adults with T2D and inadequate glycemic control were randomized (1:1:1:3) to TZP 5, 10, or 15 mg QW, or iLispro TID, as add-on to optimized insulin glargine, with or without metformin, for 52 weeks in this open-label, multicenter, Phase 3b study. HRQoL was measured at baseline and endpoint (Week 52) using the SF-36v2 acute form comprised of 8 domains and 2 component summary scores.

Results: Overall, 1428 participants with mean baseline age 59 y, T2D duration 14 y, HbA1c 8.8% and BMI 33.1 kg/m2 were randomized. At endpoint, TZP-treated participants had statistically significantly improved scores across all SF-36v2 domains and component summaries compared to iLispro-treated participants, with the largest differences observed in the General health (LS mean [SE] change 3.0 [0.31] vs. -0.1 [0.32]) and Vitality (1.5 [0.31] vs. -1.1 [0.32]) domains.

Conclusion: TZP treatment resulted in greater improvements across multiple domains of HRQoL than iLispro in adults with long standing T2D already treated with basal insulin.



Publikationsverlauf

Artikel online veröffentlicht:
18. April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany